"lung carcinoma" . . . "Hladiny sledovan\u00FDch n\u00E1dorov\u00FDch marker\u016F NSCLC byly vy\u0161\u0161\u00ED u benign\u00EDch versus malign\u00EDch n\u00E1dor\u016F. Nejvhodn\u011Bj\u0161\u00ED se uk\u00E1zal biomarker Monotal, kter\u00FD vykazoval nejv\u011Bt\u0161\u00ED specificitu a sensitivitu, zejm\u00E9na s ohledem na celkov\u00E9 i bezp\u0159\u00EDznakov\u00E9 obdob\u00ED."@cs . "1"^^ . "2007-01-01+01:00"^^ . "1. Systematick\u00E9 sledov\u00E1n\u00ED hladin parametr\u016F invazivity a metastazov\u00E1n\u00ED n\u00E1doru (NSCLC), v tumorozn\u00ED tk\u00E1ni a tumorem neposti\u017Een\u00E9 \u010D\u00E1sti pl\u00EDce pacienta s NSCLC pomoc\u00ED kvantitativn\u00ED RT-PCR a sou\u010Dasn\u011B je sledovat i imunoanalyticky v s\u00E9ru. 2. Srovn\u00E1n\u00ED senzitivity standardn\u011B pou\u017E\u00EDvan\u00FDch onkomarker\u016F NSCLC s parametry biologick\u00E9 aktivity n\u00E1doru. Ur\u010Den\u00ED optim\u00E1ln\u00ED kombinace onkomarker\u016F a parametr\u016F biologick\u00E9 aktivity n\u00E1doru v z\u00E1vislosti na histologick\u00E9m typu. 3. Vypracovat prognostick\u00FD index odhadu stupn\u011B agresivity malign\u00EDho procesu, v\u010Detn\u011B syst\u00E9mov\u00E9ho posti\u017Een\u00ED a p\u0159edpokl\u00E1dan\u00E9 odpov\u011Bdi na opera\u010Dn\u00ED a event. n\u00E1slednou adjuvantn\u00ED l\u00E9\u010Dbu nemocnc\u00FDh s NSCLC. 4. Optimalizovat v\u00FDb\u011Br pacient\u016F s NSCLC k adjuvantn\u00ED poopera\u010Dn\u00ED l\u00E9\u010Db\u011B." . "Assessment of biological activity of a tumour for prognosis and optimizing of a non- smal- cell lung carcinoma (NSCLC) therapy"@en . "1"^^ . . . . "0"^^ . "2009-12-31+01:00"^^ . "http://www.isvav.cz/projectDetail.do?rowId=NR9343"^^ . "2011-04-27+02:00"^^ . " tumour markers" . . . "Levels of investigated biomarkers in NSCLC were higher in benign versus malignant tumors. The most suitable biomarker was Monotal, which showed the highest sensitivity and specificity, particularly with respect to overall and disease free survival."@en . "8"^^ . . . "2009-12-18+01:00"^^ . "1. Systematic observation of levels of invasiveness parameters and of NSCLC tumour metastasizing parameters in a tumorous tissue, and in the part of NSCLC patient \u00B4s lung not affected by the tumour. 2. Comparison of commonly used NSCLC onco-markers sensitivity and of the parameters of a tumour biological activity. Search of the optimum combination of onco-markers and parameters of tumour biological activity in dependence on its histological type. 3. To work out an assessment prognostic index of a stage of the malignant process aggressivity, including system affection and expected response to operation and, possibly, following adjuvant therapy of NSCLC patients. 4. Optimizing of NSCLC patients selection for adjuvant post-operation treatment."@en . "8"^^ . . . " lung resection" . . "NR9343" . . " chemotherapy" . "lung carcinoma; lung resection; tumour markers; chemotherapy; RT PCR; immunoanalysis"@en . . . . . . " RT PCR" . . "Vyu\u017Eit\u00ED biologick\u00E9 aktivity n\u00E1doru pro progn\u00F3zu a optimalizaci l\u00E9\u010Dby nemalobun\u011B\u010Dn\u00E9ho karcinomu plic (NSCLC)" .